Acute Churg-Strauss Syndrome in an Asthmatic Patient Receiving Montelukast Therapy

Tang, Mark B Y; Yosipovitch, Gil

doi:10.1001/archderm.139.6.715

Cited by 9 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, leukotriene receptor antagonists were associated with the development of the Churg-Strauss syndrome [86, 87, 88, 89]. Although there are several convincing case histories, a reporting bias cannot be excluded, as recent studies indicate that overall, the incidence of Churg-Strauss syndrome has not changed in the recent past [90].…”

Section: Clinical Patterns Of Di-ildmentioning

confidence: 99%

Interstitial Lung Disease Induced by Drugs and Radiation

Camus¹,

Fanton²,

Bonniaud³

et al. 2004

Respiration

352

273

View full text Add to dashboard Cite

An ever-increasing number of drugs can reproduce variegated patterns of naturally occurring interstitial lung disease (ILD), including most forms of interstitial pneumonias, alveolar involvement and, rarely, vasculitis. Drugs in one therapeutic class may collectively produce the same pattern of involvement. A few drugs can produce more than one pattern of ILD. The diagnosis of drug-induced ILD (DI-ILD) essentially rests on the temporal association between exposure to the drug and the development of pulmonary infiltrates. The histopathological features of DI-ILD are generally consistent, rather than suggestive or specific to the drug etiology. Thus, the diagnosis of DI-ILD is mainly made by the meticulous exclusion of all other possible causes. Drug dechallenge produces measurable improvement in symptoms and imaging in the majority of patients, whereas corticosteroid therapy is indicated if symptoms are present or drug dechallenge is without an effect. Rechallenge is justified in a minority of patients, and is discouraged for diagnostic purposes only. Pneumotox^® (www.pneumotox.com) provides updated information on drug-induced respiratory disease.

show abstract

Section: Clinical Patterns Of Di-ildmentioning

confidence: 99%

Interstitial Lung Disease Induced by Drugs and Radiation

Camus¹,

Fanton²,

Bonniaud³

et al. 2004

Respiration

352

273

View full text Add to dashboard Cite

show abstract

“…This syndrome is a rare vasculitis disorder of small-and medium-size vessels and could be characterized by blood eosinophilia and eosinophilic infiltration into affected tissues [167]. Patients who experienced CSS developed eosinophilia, leucocytosis, pulmonary infiltrates, malaise, fever, rash, neuropathy, and biomarker alterations (e.g., antineutrophil cytoplasmatic antibody and serum bilirubin) [168][169][170][171][172][173][174][175][176].…”

Section: Immune System Disordersmentioning

confidence: 99%

Leukotrienes vs. Montelukast—Activity, Metabolism, and Toxicity Hints for Repurposing

Marques

Justino

2022

Pharmaceuticals

View full text Add to dashboard Cite

Increasing environmental distress is associated with a growing asthma incidence; no treatments are available but montelukast (MTK)—an antagonist of the cysteinyl leukotrienes receptor 1—is widely used in the management of symptoms among adults and children. Recently, new molecular targets have been identified and MTK has been proposed for repurposing in other therapeutic applications, with several ongoing clinical trials. The proposed applications include neuroinflammation control, which could be explored in some neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases (AD and PD). However, this drug has been associated with an increasing number of reported neuropsychiatric adverse drug reactions (ADRs). Besides, and despite being on the market since 1998, MTK metabolism is still poorly understood and the mechanisms underlying neuropsychiatric ADRs remain unknown. We review the role of MTK as a modulator of leukotriene pathways and systematize the current knowledge about MTK metabolism. Known toxic effects of MTK are discussed, and repurposing applications are presented comprehensively, with a focus on AD and PD.

show abstract

Contact Dermatitis and Drug Eruptions

2011

Andrews' Diseases of the Skin

View full text Add to dashboard Cite

Acute Churg-Strauss Syndrome in an Asthmatic Patient Receiving Montelukast Therapy

Cited by 9 publications

References 16 publications

Interstitial Lung Disease Induced by Drugs and Radiation

Interstitial Lung Disease Induced by Drugs and Radiation

Leukotrienes vs. Montelukast—Activity, Metabolism, and Toxicity Hints for Repurposing

Contact Dermatitis and Drug Eruptions

Contact Info

Product

Resources

About